Literature DB >> 29247989

Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.

Martina Molgora1, Domenico Supino1, Alberto Mantovani1,2,3, Cecilia Garlanda1,2.   

Abstract

Interleukin-1 receptor family members (ILRs) and Toll-Like Receptors (TLRs) are key players in immunity and inflammation and are tightly regulated at different levels. Most cell types, including cells of the innate and adaptive immune system express ILRs and TLRs. In addition, IL-1 family members are emerging as key players in the differentiation and function of innate and adaptive lymphoid cells. IL-1R2 and IL-1R8 (also known as TIR8 or SIGIRR) are members of the ILR family acting as negative regulators of the IL-1 system. IL-1R2 binds IL-1 and the accessory protein IL-1RAcP without activating signaling and can be released as a soluble form (sIL-1R2), thus modulating IL-1 availability for the signaling receptor. IL-1R8 dampens ILR- and TLR-mediated cell activation and it is a component of the receptor recognizing human IL-37. Here, we summarize our current understanding of the structure and function of IL-1R2 and IL-1R8, focusing on their role in different pathological conditions, ranging from infectious and sterile inflammation, to autoimmunity and cancer-related inflammation. We also address the emerging evidence regarding the role of IL-1R8 as a crucial checkpoint molecule in NK cells in anti-cancer and antiviral activity and the potential therapeutic implications of IL-1R8 blockade in specific pathological contexts.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  infection; inflammation; inflammation-associated cancer; interleukin-1

Mesh:

Substances:

Year:  2018        PMID: 29247989      PMCID: PMC5922415          DOI: 10.1111/imr.12609

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  176 in total

1.  Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Linda D Hazlett
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

3.  IL-37 requires IL-18Rα and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice.

Authors:  L Lunding; S Webering; C Vock; A Schröder; D Raedler; B Schaub; H Fehrenbach; M Wegmann
Journal:  Allergy       Date:  2015-01-26       Impact factor: 13.146

4.  The single IgG IL-1-related receptor controls TLR responses in differentiated human intestinal epithelial cells.

Authors:  Mohammed A Khan; Theodore S Steiner; Ho Pan Sham; Kirk S Bergstrom; Jingtian T Huang; Kiran Assi; Bill Salh; Isabella T Tai; Xiaoxia Li; Bruce A Vallance
Journal:  J Immunol       Date:  2010-02-03       Impact factor: 5.422

5.  Severe Listeria monocytogenes infection induces development of monocytes with distinct phenotypic and functional features.

Authors:  Douglas A Drevets; Jennifer E Schawang; Vinay K Mandava; Marilyn J Dillon; Pieter J M Leenen
Journal:  J Immunol       Date:  2010-07-14       Impact factor: 5.422

6.  IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8.

Authors:  Ceire Costelloe; Melanie Watson; Aine Murphy; Keith McQuillan; Christine Loscher; Michelle E Armstrong; Cecilia Garlanda; Alberto Mantovani; Luke A J O'Neill; Kingston H G Mills; Marina A Lynch
Journal:  J Neurochem       Date:  2008-02-18       Impact factor: 5.372

Review 7.  TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization.

Authors:  Cecilia Garlanda; Hans-Joachim Anders; Alberto Mantovani
Journal:  Trends Immunol       Date:  2009-08-21       Impact factor: 16.687

8.  The expression pattern of TIR8 is conserved among vertebrates.

Authors:  Federica Riva; Nadia Polentarutti; Giulia Tribbioli; Alberto Mantovani; Cecilia Garlanda; Lauretta Turin
Journal:  Vet Immunol Immunopathol       Date:  2009-03-24       Impact factor: 2.046

Review 9.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

10.  A Pseudomonas aeruginosa TIR effector mediates immune evasion by targeting UBAP1 and TLR adaptors.

Authors:  Paul Rc Imbert; Arthur Louche; Jean-Baptiste Luizet; Teddy Grandjean; Sarah Bigot; Thomas E Wood; Stéphanie Gagné; Amandine Blanco; Lydia Wunderley; Laurent Terradot; Philip Woodman; Steve Garvis; Alain Filloux; Benoit Guery; Suzana P Salcedo
Journal:  EMBO J       Date:  2017-05-08       Impact factor: 11.598

View more
  31 in total

Review 1.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 2.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

Authors:  Alberto Mantovani; Charles A Dinarello; Martina Molgora; Cecilia Garlanda
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

3.  Cancer type classification using plasma cell-free RNAs derived from human and microbes.

Authors:  Shanwen Chen; Yunfan Jin; Siqi Wang; Shaozhen Xing; Yingchao Wu; Yuhuan Tao; Yongchen Ma; Shuai Zuo; Xiaofan Liu; Yichen Hu; Hongyan Chen; Yuandeng Luo; Feng Xia; Chuanming Xie; Jianhua Yin; Xin Wang; Zhihua Liu; Ning Zhang; Zhenjiang Zech Xu; Zhi John Lu; Pengyuan Wang
Journal:  Elife       Date:  2022-07-11       Impact factor: 8.713

4.  Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients.

Authors:  Xiaoming Yang; Alex C Rutkovsky; Juhua Zhou; Yin Zhong; Julian Reese; Timothy Schnell; Helmut Albrecht; William B Owens; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2022-04-04       Impact factor: 5.426

Review 5.  IL-37: An anti-inflammatory cytokine with antitumor functions.

Authors:  Yu Mei; Haiyan Liu
Journal:  Cancer Rep (Hoboken)       Date:  2018-11-22

Review 6.  Introduction to the interleukin-1 family of cytokines and receptors: Drivers of innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 7.  Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells.

Authors:  Paul-Gydéon Ritvo; David Klatzmann
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

8.  Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease.

Authors:  Dennis M de Graaf; Ralph J A Maas; Sanne P Smeekens; Elan Eisenmesser; Jasmina S Redzic; Monique M Helsen; Nicholas E Powers; Suzhao Li; Vassili Kalabokis; Mark S Gresnigt; Leo A B Joosten; Charles A Dinarello; Frank L van de Veerdonk
Journal:  Cytokine       Date:  2020-10-28       Impact factor: 3.861

9.  Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation.

Authors:  Xuehui Zhang; Chaoyuan Huang; Biyu Cui; Yebin Pang; Rong Liang; Xiaoling Luo
Journal:  Dis Markers       Date:  2021-04-27       Impact factor: 3.434

Review 10.  Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.

Authors:  Chaopin Yang; Yue Li; Yaozhang Yang; Zhiyi Chen
Journal:  J Immunol Res       Date:  2020-01-21       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.